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Objective: The objective of this analysis was to investigate whether patients with severe
or difficult-to-treat asthma who experienced recent severe asthma exacerbations are at
increased risk of future asthma exacerbations.
Methods: We conducted a 1.5-year prospective analysis of 2780 patientsX12 years of age
from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
study. Severe exacerbations were defined as either an asthma-related emergency
department visit or night of hospitalization in the 3 months prior to study visit; a
secondary analysis assessed prior steroid bursts as an independent predictor and outcome.
Potential confounding was assessed by statistical adjustment for demographic and clinical
factors, as well as asthma severity and asthma control.
Results: Compared with patients without a recent severe exacerbation, patients with a
recent exacerbation were at increased risk of future exacerbation (odds ratio ¼ 6.33; 95%
CI 4.57, 8.76), even after adjustment for demographics and clinical factors (odds
ratio ¼ 3.77; 95% CI 2.62, 5.43), asthma severity (physician-assessed: odds ratio ¼ 5.62;
95% CI 4.03, 7.83), National Asthma Education and Prevention Program (odds ratio ¼ 5.07;
95% CI 3.62, 7.11), Global Initiative for Asthma (odds ratio ¼ 5.32; 95% CI 3.80, 7.47), and
asthma control (odds ratio ¼ 3.90; 95% CI 2.77, 5.50).
Conclusion: This analysis suggests that recent severe asthma exacerbations are a strong
independent factor predicting future exacerbations and, as such, should be considered as
part of the clinical assessment of patients with severe or difficult-to-treat asthma.
& 2006 Published by Elsevier Ltd.Published by Elsevier Ltd.
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In 2003, nearly 20 million Americans reported having asthma
and over half reported having an asthma attack.1 An
important factor in asthma management is the reduction
of exacerbations that require intensive healthcare use.
Identification of patients at greatest risk for future exacer-
bations would help focus available healthcare resources,
improve prevention strategies, and reduce morbidity of
asthma.
Studies of asthma populations have shown that patients
with a history of asthma exacerbations are at significant risk
for future exacerbations.2–11 Chronic under-medication,3
poor lung function,10 presence of comorbid conditions,4
poor quality of life and/or symptom control,12 and asthma
severity3,4,7–10 have been identified in several asthma
studies as contributing factors to this relationship. It has
not been established, however, whether the association
between recent exacerbations and future exacerbations
persists after controlling for guideline-assessed asthma
severity, asthma control, and clinical and demographic
factors in patients with severe or difficult-to-treat asthma.
The Epidemiology and Natural History of Asthma: Out-
comes and Treatment Regimens (TENOR) is a 3-year, multi-
center, observational study of the natural history, treatment
regimens, and outcomes of subjects with severe or difficult-
to-treat asthma. The objective of this analysis was to
investigate whether patients with severe or difficult-to-
treat asthma who experienced recent asthma exacerbations
are at increased risk of future asthma exacerbations,
independent of known risk factors, as well as measures of
severity and control. This analysis adjusted for demographic
and clinical risk factors, asthma severity (National Asthma
Education and Prevention Program (NAEPP),13,14 Global
Initiative for Asthma (GINA),15 and physician-assessed16),
as well as patient-reported asthma control.17 Our hypothesis
was that recent exacerbations would persist in being an
important indicator of future exacerbations, despite adjust-
ment for severity and other potential risk factors.
Methods
Study design and population
TENOR is a prospective, observational, multicenter, 3-year
study of patients in the United States with severe or
difficult-to-treat physician-diagnosed asthma. Complete
details of TENOR study methods have been previously
described.18
Briefly, patients were eligible for TENOR if they were
categorized by physicians as having severe or difficult-to-
treat asthma; patients with mild or moderate asthma were
eligible for enrollment if their physicians considered their
asthma difficult-to-treat and they met the additional
inclusion and exclusion criteria. Patients were excluded
from TENOR if they were heavy smokers (X30 pack-years)
and if they had cystic fibrosis. Patients were selected for the
TENOR study if they had received care for at least 1 year
from their current provider and if they demonstrated high
healthcare or medication usage in the 12 months prior to
study entry.18 High healthcare utilization (HCU) was definedas 2 or more unscheduled care visits for asthma or 2 or more
oral steroid bursts. High medication use was defined at the
time of enrollment as requiring 3 or more medications to
control asthma or requiring long-term, daily high doses of
inhaled steroids or use of 5mg/d or more of oral prednisone.
Data collection
Data utilized for this analysis was collected at the 12-month
visit and subsequent 6-month visits. Demographic data
collected in TENOR included age, sex, race/ethnicity.
Clinical data included body mass index (BMI), spirometry
measurements, as well as histories of comorbid conditions,
smoking, and allergic/non-allergic triggers collected by the
study site physician and/or study coordinator. Current
actual asthma control medication use, including asthma
control and quick-relief medications were collected by study
coordinator interview. To collect medication data as
accurately and consistently as possible, patients were
instructed to bring their medications to the interview.
However, medication use was not verified against prescrip-
tions. Controller medications included inhaled corticoster-
oids, long-acting beta-agonists, leukotriene modifiers,
methylxanthines, and cromolyn sodium or nedocromil.
Quick-relief medications included short-acting beta-agonists
and anticholinergics. Systemic corticosteroid use was also
collected. Patient-reported information on asthma-related
HCU included emergency department (ED) visits, overnight
hospitalizations, corticosteroid bursts or ‘steroid bursts’
(defined as a short-term increase in corticosteroid therapy
to treat an exacerbation of symptoms), and unscheduled
office visits/contacts to physician during the previous 3
months; confirmation with patient medical records was not
done.
Asthma severity assessment
Asthma severity was assessed using three different methods.
Physicians were instructed to use their subjective clinical
opinion to categorize each patient as having either mild,
moderate, or severe asthma. In addition to assessing each
subject’s asthma severity, physicians reported whether their
patient’s asthma was considered difficult-to-treat based on
specified parameters (i.e., complex treatment regimen,
multiple drugs required, unable to avoid triggers, frequent
exacerbations, severe exacerbations and/or unresponsive to
therapy). Asthma severity was also derived according
to NAEPP and GINA guidelines using patient responses to
questions relating to asthma symptoms from the patient-
reported Mini Asthma Quality of Life Questionnaire (Mini
AQLQ)19 along with patient-reported asthma medication
use. Complete details of this categorization have been
described previously.16 The Asthma Therapy Assessment
Questionnaire (ATAQ)17 was used to evaluate patient-
reported level of asthma control.
Asthma exacerbations: predictor and outcomes
Recent severe exacerbations as a predictor were defined as
the composite outcome of an ‘asthma-related ED visit or
night of hospitalization in the 3 months prior to the study
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TENOR recent exacerbations analysis 483visit.’ Future severe exacerbations (FSE) as outcome at
18-month follow-up were defined as an ‘asthma-related ED
visit or night of hospitalization in the 3 months prior to the
study visit, or an asthma-related death that occurred prior
to the scheduled study visit.’ These definitions were chosen
because these serious events would likely result in medical
encounters, therefore minimizing incomplete or misclassi-
fied data. There were few deaths in TENOR; therefore FSE is
mostly a composite of hospitalization and ED visits.
Secondly, ‘any steroid burst in the 3 months prior to the
study visit’ assessed at baseline and 18-month follow-up was
used as a more sensitive measure of exacerbation as
predictor and outcome, respectively. Steroid bursts were
defined as a short-term increase in steroid therapy to treat
an exacerbation of asthma symptoms. This definition was
used only for the secondary analysis.Statistical analysis
The present analysis includes patientsX12 years of age who
had both a 12-month follow-up assessment and at least 1
subsequent follow-up visit. In order to avoid potential over-
reporting of HCU due to the TENOR inclusion criteria, the
12-month assessment was used at baseline for this analysis
and the TENOR 30-month assessment is used for this study’s
1.5-year (18-month) follow-up outcome. Use of a single
follow-up visit allowed outcomes to be defined as binary
variables that could be modeled using logistic regression.
For patients without an 18-month visit, data was imputed
using the nearest available post-baseline follow-up visit.
Recent exacerbations, the three asthma severity mea-
sures and asthma control were used in univariable and
bivariable models of the outcomes. In addition, a set of
candidate predictor variables were pre-specified from
demographic and clinical variables collected at baseline.
Candidate variables included age; sex; race; BMI (kg/m2);
duration of asthma; smoking status; history of chronic
obstructive pulmonary disease (COPD), emphysema, and
chronic bronchitis; post-bronchodilator forced expiratory
volume in 1 s (FEV1), forced expiratory vital capacity (FVC)
ratio; post-bronchodilator % predicted FVC; allergic rhinitis;
count of allergic asthma triggers (i.e., pollen, dust, mold,
pets); and the count of non-allergic asthma triggers (i.e.,
cold and sinus infections). This set of candidate predictors
was evaluated using stepwise selection and the reduced
subset was then used in a multivariable model. Interactions
between recent exacerbations and seasonality were also
assessed, but no interaction was detected; therefore, these
results are not presented.
Confirmatory analyses were conducted using generalized
estimating equations (GEE) repeated measures logistic
regression model. The GEE method employs all available
follow-up data and accounts for multiple correlations.20
With GEE, the analysis utilized all 4 of the patients’ possible
follow-up assessments so that the outcome covered 6–24
months of follow-up rather than only the 18-month out-
come. The GEE results were very similar to the logistic
regression results and are therefore not presented.
Odds ratios (ORs) were computed first using recent
exacerbations as the only predictor. Adjustment for asthma
severity was accomplished using a set of multivariablemodels, each of which included RSE and a single severity
measure. Adjustment for demographics and clinical data
included the previously identified covariates in the logistic
regression. Asthma-related medications were not consid-
ered as a separate model adjustment because they are a
component of the GINA classification. Primary results are
based on adjustments for the collection of variables in the
stepwise model or one of the individual measures of asthma
control or severity. Adjustment for all of measures in a single
statistical model may create issues of colinearity; however,
for completeness, results from the single statistical model
have been reported. Where measures of precision are
reported,21 95% confidence intervals were used and percen-
tages were computed as a function of non-missing data. All
analyses were conducted using SAS version 9.1.
Results
Demographics by RSE
Of the entire TENOR population, 2780 patients met the
criteria for this analysis, including 244 (8.8%) who had an
RSE. Among these 244 patients, 155 had a prior ED visit, 17
had a hospitalization, and 72 had both an ED visit and
hospitalization. There were 2536 patients with no recent
severe exacerbations (NRSE). Nearly 700 patients (n ¼ 679)
had a recent steroid burst.
Patients in the RSE group were more likely to be young
adults (18% vs. 11% in the NRSE group) (Table 1). The gender
distribution in this analysis reflected the entire TENOR
population, where 71% of patients X18 years of age were
female.15 Patients in the RSE cohort were also more likely to
be black (30%; Po0:001), overweight (49% with a BMI X30;
P ¼ 0:018), and have a history of bronchitis (42%; P ¼ 0:002)
compared with only 11%, 39%, and 32%, respectively, in the
NRSE group. Patients with RSE were more likely to have
multiple allergic triggers (57% with X2; P ¼ 0:002) and
multiple non-allergic triggers (49% with X2; Po0:001)
compared with patients in the NRSE group (44% and 26%),
respectively.
Asthma severity and asthma control by RSE
More patients in the RSE group had severe asthma by all
measures compared with patients in the NRSE group.
Patients in the RSE cohort had more asthma control
problems than the NRSE patients (Table 2).
RSE in predicting FSE
The odds of RSE predicting FSE were over 6-fold (OR ¼ 6.33;
95% CI 4.57, 8.76) (Fig. 1a). After adjustment for asthma
severity by physician-assessment, there was over a 5-fold
risk of FSE (OR ¼ 5.62; 95% CI 4.03, 7.83). When adjusted by
guideline assessment (OR ¼ 5.07; 95% CI 3.62, 7.11) for
NAEPP and (OR ¼ 5.32; 95% CI 3.80, 7.47) for GINA.
Adjustment for asthma control resulted in an OR of 3.90
(95% CI 2.77, 5.50) and adjustment for demographic and
clinical characteristics produced an OR of 3.77 (95% CI 2.62,
5.43). Although many of the components of severity are
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Table 1 Baseline TENOR patient demographics and characteristics.
Characteristic NRSE, n (%) RSE, n (%) P value
Total patients (n ¼ 2780) 2536 (91.2) 244 (8.8)
Age o0.0001
12–18 421 (16.6) 46 (18.9)
19–35 285 (11.2) 45 (18.4)
36–54 940 (37.1) 101 (41.4)
X55 890 (35.1) 52 (21.3)
Female 1673 (66.0) 170 (69.7) 0.2426
Race o0.0001
White (n ¼ 2230) 2076 (81.9) 154 (63.1)
Black (n ¼ 352) 279 (11.0) 73 (29.9)
Othery 181 (7.1) 17 (7.0)
Body mass index 0.0045
X30 982 (39.1) 116 (48.5)
Smoking status 0.0122
Currentz 63 (2.5) 13 (5.3)
Former 688 (27.1) 54 (22.1)
Never 1785 (70.4) 177 (72.5)
History of bronchitis 814 (32.1) 102 (41.8) 0.0021
Post-bronchodilator % predicted FVC
p60 125 (5.2) 24 (10.6) 0.0002
60–80 541 (22.4) 64 (28.2)
480 1752 (72.5)z 139 (61.2)
Post-bronchodilator % predicted FEV1
p60 427 (17.7) 57 (25.1) o0.0001
60–80 680 (28.1) 86 (37.9)
480 1310 (54.2)z 84 (37.0)
Allergic triggersy 0.0002
0–1 1398 (55.6) 105 (43.2)
X2 1116 (44.4)z 138 (56.7)z
Non-allergic triggersy o0.0001
0–1 1848 (73.5) 124 (51.1)
X2 666 (26.5)z 119 (49.0)z
NRSE ¼ no recent severe exacerbation; RSE ¼ recent severe exacerbation.
For entire category.
yOther racial groups that comprised the total TENOR cohort were: Hispanic (n ¼ 122), Asian/Pacific Islander (n ¼ 47), and other
(n ¼ 29).
zCurrent smokers comprised 2.7% (n ¼ 76) of the total TENOR cohort.
zThese numbers do not add up to 2536 or 244 because of missing data.
yAllergic triggers included were pollen, dust, pets, and mold; non-allergic triggers were cold/sinus and emotional triggers.
M.K. Miller et al.484captured in the adjustment for demographic and clinical
characteristics, a model adjusting for asthma control, all
three measures of severity, and demographic and clinical
characteristics produced an OR of 3.09 (95% CI 2.35, 4.06).
When steroid bursts were defined as predictor and
outcome, patients with a recent exacerbation were also
more likely to report a future exacerbation (unadjusted
OR ¼ 3.91; 95% CI 3.28, 4.67) (Fig. 1b). The odds of having a
future steroid burst were also statistically significant
(Po0:0001) after adjusting for severity classification, ATAQ
control index and/or demographic and clinical character-
istics. Adjustment for all variables in a single model led to
an OR of 2.99 (95% CI 2.57, 3.47)Tables 3a and 3b show the relationship between recent
exacerbations and future exacerbations after adjustment
for level of asthma severity. Asthma severity classification of
severe vs. moderate nearly doubled the odds of a future
severe exacerbation, regardless of the classification me-
chanism. Patients with X2 asthma control problems were
also at increased risk (OR ¼ 2.00, 95% CI 1.37, 2.92;
P ¼ 0:0003). A similar pattern was seen when recent steroid
bursts were assessed as predicting future steroid bursts
(Table 3b).
Multivariate analysis found that RSE remained signifi-
cantly associated with FSE after additional covariate
adjustment. Patients with BMI 430, non-allergic or allergic
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Table 2 Baseline TENOR measures of asthma severity and asthma control.
Assessment Method NRSE, n (%) RSE, n (%)
Total patients (N ¼ 2780) 2536 244
Physician-assessed severity
Mild 182 (7.2) 8 (3.3)
Moderate 1346 (53.2) 83 (34.2)
Severe 1002 (39.6) 152 (62.6)
NAEPP severity
Mild 1025 (41.5) 43 (18.0)
Moderate 689 (27.9) 61 (25.5)
Severe 756 (30.6) 135 (56.5)
GINA severity
Mild 145 (5.9) 2 (0.8)
Moderate 1128 (46.2) 55 (23.1)
Severe 1170 (47.9) 181 (76.1)
ATAQ control index
0 835 (34.2) 7 (2.9)
1 630 (25.8) 30 (12.6)
X2 979 (40.1) 201 (84.5)
Recent steroid burst 679 (26.8) 191 (78.6)
NRSE ¼ no recent severe exacerbation; RSE ¼ recent severe exacerbation; NAEPP ¼ National Asthma Education and Prevention
Program; GINA ¼ Global Initiative for Asthma; ATAQ ¼ Asthma Therapy Assessment Questionnaire.
Po0.0001 for patients experiencing an exacerbation vs. not experiencing an exacerbation for all assessment methods used.
TENOR recent exacerbations analysis 485triggers were at increased risk of FSE while lower FVC, white
race/ethnicity or age 455 years were protective factors of
risk. Similarly, recent steroid bursts were significantly
associated with future steroid bursts after multivariate
adjustment. Having a history of COPD, non-allergic triggers
or being a young adult increased risk of future exacerbations
while lower FEV1/FVC ratio or white race/ethnicity were
protective (Table 4).Discussion
This analysis has found that recent severe asthma exacer-
bations are strongly associated with future exacerbations,
most notably demonstrated by an OR of 6.33 (95% CI 4.57,
8.76) for RSE predicting FSE. When steroid bursts were used
to define exacerbation and after risk factor adjustment, the
association persisted. This implies that recent severe
exacerbations are a strong independent factor predicting
future exacerbations and should be considered when
clinically evaluating patients with severe or difficult-to-
treat asthma. For appropriate disease management, it is
imperative to understand the factors contributing to
recurrent and intense HCU in ‘‘frequent flier’’11 patients,
such as those in TENOR.
Although the relationship between previous and future
asthma exacerbations have been studied previously2–11
these results expand upon previous research by using
prospectively evaluated data and including more than a
year of patient follow-up in a unique cohort of patients with
severe and difficult-to-treat disease. In addition, our study
used a large asthma patient sample and sizeable numbers ofclinical predictor and outcome variables, including mea-
sures of asthma severity and asthma control. These aspects
of our study allowed for a thorough and robust examination
of risk factors for future exacerbations in severe or difficult-
to-treat asthma. The current analysis also controlled for
important potential confounding variables, such as asthma
severity and asthma control, which were not previously
addressed in other studies.
While a lack of agreement between asthma severity
classification by physicians’ assessment, NAEPP, and GINA
criteria exists, it has been reported that a relationship exists
between recent HCU and asthma severity, by several
measures.16 We found recent exacerbations were predictive
of future exacerbations after adjustment for asthma
severity by three different asthma severity classification
methods and that patients with severe asthma were at
greatest risk. This finding suggests that recent exacerbations
are not adequately represented in asthma severity classifi-
cations, even when those classifications incorporate treat-
ment as is the case with the GINA guidelines. However, when
asthma control was included in the model, the odds ratio
(OR ¼ 3.90; 95% CI 2.77, 5.50) was lower than in the asthma
severity models. This suggests that asthma control better
reflects risk of future asthma exacerbations than measures
of asthma severity. Therefore, patient-reported asthma
control may be an intermediate concept between asthma
severity assessment and recent exacerbations.
Our findings are consistent with results from other studies
which identified certain demographic and clinical risk
factors associated with future exacerbations. Specifically,
patients with BMI greater than 30, non-allergic or allergic
triggers, non-white race/ethnicity, lower % predicted FVC or
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Figure 1 Odds of future exacerbations associated with recent exacerbations, adjusted for demographics, asthma severity, and
asthma control. (a) Odds of future severe exacerbation associated with recent severe exacerbations, (b) Odds of future steroid burst
associated with recent steroid bursts. x-Axis is on logarithmic scale.
M.K. Miller et al.486history of COPD were at greater risk of future exacerbations
compared with patients without these characteristics.
The FVC finding may be related to air trapping in the
context of an obstructive ventilatory deficit or a proxy for
restrictive lung physiology associated with obesity, which
was relatively common in our study group. The role of
obesity in asthma may have mechanical, inflammatory, and
hormonal influences22; however, our analysis findings could
be related to steroid use, which also was prominent in the
TENOR population. Older patients (aged 455) were identi-fied as being at lowest risk of FSE while young adults (ages
19–35) were found to be at higher risk of future steroid
bursts compared with adolescents (ages 12–18). These
mixed age-related findings may be explained by lifestyle
differences, including use of medications and healthcare
resources, or could be due to biological differences between
these age groups. Additionally, recent research23 has found
that, independently, viral illness and allergen exposure did
not increase the likelihood of asthma-related hospitaliza-
tions in children; however, in combination, these factors did
ARTICLE IN PRESS
Table 3b Predictors of future steroid bursts.y
Predictors OR 95% CI
Unadjusted
Recent exacerbations 3.91 (3.28, 4.67)
Adjusted
Physician-assessed severity
Recent exacerbations 3.47 (2.90, 4.16)
Severe vs. moderate asthma 1.87 (1.56, 2.25)
NAEPP guidelines severity
Recent exacerbations 3.58 (2.98, 4.30)
Severe vs. moderate asthma 1.43 (1.15, 1.79)
GINA guidelines severity
Recent exacerbations 3.62 (3.01, 4.37)
Severe vs. moderate asthma 1.49 (1.23, 1.81)
ATAQ control index
Recent exacerbations 3.23 (2.67, 3.90)
X2 vs. 1 ATAQ control problems 1.48 (1.18, 1.86)
yFuture steroid burst ¼ ‘Any steroid burst in the 3 months prior to the 18 month study visit.’; NAEPP ¼ National Asthma Education
and Prevention Program; GINA ¼ Global Initiative for Asthma; ATAQ ¼ Asthma Therapy Assessment Questionnaire.
Table 3a Odds of future exacerbations associated with recent exacerbations adjusted for asthma severity assessment and
asthma control. Predictors of future severe exacerbations (FSE).
Predictors OR 95% CI
Unadjusted
Recent exacerbations 6.33 (4.57, 8.76)
Adjusted
Physician-assessed severity
Recent exacerbations 5.62 (4.03, 7.83)
Severe vs. moderate asthma 1.70 (1.26, 2.29)
NAEPP guidelines severity
Recent exacerbations 5.07 (3.62, 7.11)
Severe vs. moderate asthma 1.81 (1.26, 2.59)
GINA guidelines severity
Recent exacerbations 5.32 (3.80, 7.47)
Severe vs. moderate asthma 1.87 (1.35, 2.59)
ATAQ control index
Recent exacerbations 3.90 (2.77, 5.50)
X2 vs. 1 ATAQ control problems 2.00 (1.37, 2.92)
Future severe exacerbation ¼ the composite outcome of an ‘asthma-related ED visit’ or ‘night of hospitalization’ in the 3 months
prior to the 18-month study visit, or an asthma-related death that occurred prior to the scheduled 18-month study visit;
NAEPP ¼ National Asthma Education and Prevention Program; GINA ¼ Global Initiative for Asthma; ATAQ ¼ Asthma Therapy
Assessment Questionnaire.
TENOR recent exacerbations analysis 487increase hospitalization risk. While our analysis found no
association between seasonality and RSE, future TENOR
analyses may help clarify the role of allergic triggers in the
relationship between RSE and FSE in patients with severe or
difficult-to-treat asthma.This study has several limitations. Steroid bursts as
predictor identified more recent exacerbations (n ¼ 870)
compared with severe exacerbations (n ¼ 244); however,
steroid bursts may be a less-specific measure of exacerba-
tions compared with RSE and may be subject to recall bias.
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Table 4 Odds of future exacerbations using multivariate analysis adjusted for demographic and clinical factors.
Risk factors OR 95% CI
Future severe exacerbations
Recent severe exacerbation 3.77 (2.62, 5.43)
BMI 430 1.67 (1.21, 2.31)
Non-allergic triggers 1.44 (1.15, 1.80)
Allergic triggers 1.14 (1.01, 1.29)
Per 10% predicted FVC 0.87 (0.80, 0.95)
Race: white vs. non-white 0.63 (0.45, 0.89)
Age: 455 vs. 12–18 0.57 (0.34, 0.94)
Future steroid burst
Recent steroid burst 3.28 (2.72, 3.96)
COPD 1.67 (1.19, 2.34)
Non-allergic triggers 1.57 (1.38, 1.79)
Age: 19–35 vs. 12–18 1.42 (1.00, 2.01)
Per 10% predicted FEV1/FVC ratio 0.94 (0.89, 0.99)
Race: white vs. non-white 0.77 (0.61, 0.97)
BMI ¼ body mass index; FVC ¼ forced vital capacity; COPD ¼ chronic obstructive pulmonary disease; FEV1 ¼ forced expiratory volume
in 1 s.
M.K. Miller et al.488Also, the primary and secondary analysis predictors and
outcomes are not mutually exclusive as severe exacerba-
tions occurring under supervision of appropriate asthma
medical care likely resulted in steroid bursts.
In TENOR, there may be over-reporting of exacerbations
by patients at earlier assessment visits than at later visits;
therefore, we used the 12-month visit as baseline. Addi-
tionally, use of a 3-month patient recall period for HCU has
been shown to be a more precise patient recall period than
longer periods.24,25 Also, it is not clear which clinical
parameters physicians used in classifying patient severity.
Furthermore, NAEPP and/or GINA criteria-based severity
assessments were derived retrospectively, from patient-
reported outcome instruments that were not designed to
evaluate asthma severity and may not fully represent
asthma severity.
Our results suggest that recent severe exacerbations
should be given greater consideration in the clinical
evaluation of patients with severe or difficult-to-treat
asthma. Furthermore, after consideration of other factors,
including asthma severity classification and control, recent
asthma exacerbations were found to contribute strongly and
independently to the prediction of a future exacerbation.
This suggests that the pathobiologic events driving these
exacerbations may differ from those contributing to other
characteristics of asthma. Physicians should be aware of
their patients’ recent exacerbation status and respond to
the occurrence to reduce the risk of repeat episodes.
Asthma treatment guidelines should consider recent exacer-
bations in determination of asthma severity classification
and recommendations for treatment intervention to prevent
future events.References
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